The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

Dual-target CAR CAR T cell therapy is a form of personalized immunotherapy that uses a patient's own immune cells to treat their cancer. While widely successful in blood cancers, CAR T cell ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, the largest study examining its use in a community setting has found. CAR-T is shorthand for ...

CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine ...

When the symptoms and inflammation are not brought under control, they can cause organ damage. Like other cell therapies, CAR T cell therapy uses a modified cell either from the patient or from a ...

For decades, immunologists have explored CAR-T cell therapy as an effective tool to fight blood cancer. Increasingly, CAR-T cells are being explored as a potential silver bullet for treating ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...